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Introduction: Central (superior vena cava, brachiocephalic, or subclavian) venous stenoses are a major impediment to
long-term arteriovenous access in the upper extremities. The optimal management of these stenoses is still undecided. The
purpose of this study was to determine the outcomes of primary angioplasty (PTA) vs primary stenting (PTS) in a dialysis
access population at a tertiary referral academic medical center.
Methods: A database of consecutive hemodialysis patients undergoing endovascular treatment for central venous stenosis
was developed for the period 1995 through 2003. This database was retrospectively reviewed. Vessels exposed to either
primary high-pressure balloon angioplasty or primary stenting were examined. Vessels undergoing stenting after failed or
suboptimal angioplasty were defined as failures at the time of stenting despite the potential continued patency upon
completion of stenting. Kaplan-Meier survival analyses were performed to assess time-dependent outcomes. Cox
proportional hazards analysis was performed for time-dependent variables. Data are presented as mean  standard
deviation where appropriate.
Results: PTS was used to treat 26 patients (35% male; average age, 57  15 years) with 26 central venous stenoses, and
47 patients (45% male; average age, 57  18 years) with 49 central venous stenoses were treated with PTA. The PTS
group underwent 71 percutaneous interventions per stenosis (average, 2.7  2.4 interventions), and the PTA group
underwent 98 interventions per stenosis (average, 2.0  1.6 interventions). The PTS group hemodialysis access site was
an average of 1.0 1.3 years old at the time of the initial intervention, and the hemodialysis access in the PTA group was
an average of 1.1 1.2 years old. Primary patency was equivalent between groups by Kaplan-Meier analysis, with 30-day
rates of 76% for both groups and 12-month rates of 29% for PTA and 21% for PTS (P  .48). Assisted primary patency
was also equivalent (P  .08), with a 30-day patency rate of 81% and 12-month rate of 73% for the PTA group, vs PTS
assisted patency rates of 84% at 30 days, and 46% at 12 months. Ipsilateral hemodialysis access survival was equivalent
between groups.
Conclusions: Endovascular therapy with PTA or PTS for central venous stenosis is safe, with low rates of technical failure.
Multiple additional interventions are the rule with both treatments. Although neither offers truly durable outcomes, PTS
does not improve on the patency rates more than PTA and does not add to the longevity of ipsilateral hemodialysis access
sites. ( J Vasc Surg 2007;45:776-83.)The number of patients presenting for hemodialysis
access and the required duration of access is growing.
Management of the complications of hemodialysis access is
now integral to vascular practice, and there is significant
onus to maintain patency of existing grafts. Central venous
stenosis potentially compromises this patency by diminish-
ing flow1 or by leading to venous hypertension and inca-
pacitating extremity edema, necessitating access ligation for
symptom relief. It is consequently becoming a major im-
pediment to dialysis access management.
Meanwhile, the management of central venous stenosis
is evolving. Although open surgical treatment has demon-
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776strated durability in the past, it was associated with signifi-
cant morbidity. As a result, interest in percutaneous man-
agement has increased. Percutaneous treatment for central
venous stenosis is feasible, efficient, and perceived as
patient-friendly.
The endovascular management options include high-
pressure balloon angioplasty, intravascular stenting, and,
more recently, cutting balloon angioplasty. The optimal
management strategy is unknown, however. We retrospec-
tively examined the outcomes of primary angioplasty vs
primary stenting of central venous stenoses in patients with
compromised upper extremity hemodialysis access at our
institution. Patients undergoing secondary stenting for
failed or suboptimal angioplasty were excluded.
METHODS
Study setting. This study was performed at a univer-
sity medical center in a metropolitan area of 1 million
persons and an overall catchment area of approximately 5
million in Western New York State. A database was main-
tained of all patients undergoing endovascular treatment of
central venous stenoses in the course of managing dialysis
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treated with primary angioplasty or primary stenting during
this time period were followed up through 2005.
Study design. A review was undertaken of hospital
and office charts of patients captured in this time period.
For each patient, we identified date(s) of access creation,
dates of percutaneous intervention, indications for central
venous stenosis interventions, graft failure, dialysis catheter
placement, as well as demographics, symptoms, existing
comorbid conditions, and risk factors for atherosclerosis.
Technique. A single puncture technique was used at
the hemodialysis access site to enter the venous system in
patent grafts, and a double puncture technique was em-
ployed in thrombosed grafts. Contrast central venous
venography is part of the diagnostic imaging performed
during any intervention on a dialysis access site in the
extremity. The angioplasty balloons used in this study were
Bard (Murray Hill, NJ) and Boston Scientific (Natick,
Mass), with burst pressures of 8 to 15 atm and operational
pressures of 10 to 20 atm. Intravascular stents used in all
cases except one were the Wallstent (Boston Scientific),
with diameters of 8 to 12 mm and lengths of 42 to 94 mm.
These are bare, self-expanding stainless steel stents. One
patient received a 10-mm 40-mm Smart (Cordis, Johnson
& Johnson, Miami, Fla) stent at the time of primary stent
deployment. This is a bare, self-expanding nitinol stent.
Failure was considered as either an anatomic defect
requiring therapy, restenosis or occlusion noted on subse-
quent venography, computed tomography angiography, or
magnetic resonance angiography, or recurrence of ipsilat-
eral upper extremity swelling if present before therapy. In
addition, placement of a stent at a given patient’s index
lesion within the angioplasty group was also considered
failure of angioplasty, and follow-up was discontinued for
that patient at that time point. Likewise, patients undergo-
ing secondary stenting for a failed or suboptimal angio-
plasty result at the initial angioplasty were defined as failures
of primary angioplasty at time zero.
Events considered end points to functional access status
were placement of new access site, resection of access site,
ligation of access site, and dialysis catheter placement. Data
were collected on the success rate, complication rate, long-
term patency, and presence and location of stenosis.
Venograms were reviewed in all cases to assess lesion char-
acteristics and preprocedure and postprocedure results.
Results were standardized to current Society of Interven-
tional Radiology and Society for Vascular Surgery (SVS)
criteria.2,3 We do not use subclavian vein catheters in any
dialysis access patient as a unit policy.
Definitions. A major complication was defined as any
event, regardless of how minimal, not routinely observed
after endoluminal therapy that required treatment with a
therapeutic intervention or rehospitalization 30 days of
the procedure.
Primary patency was defined as a patent central vein
without recurrent stenosis or the need for further interven-
tion within the central veins. Assisted primary patency was
defined as a patent central vein that underwent furtherintervention to improve patency. Loss of patency was de-
fined according to accepted reporting standards.
Technical failure was defined as 50% gain in luminal
diameter. Early failure was defined as an inability to cross
the lesion at the time of the primary procedure or by the
presence of an occlusion or50% restenosis within the first
30 days after the initial procedure.
Residual stenosis was defined as 30% remaining ste-
nosis at the conclusion of intervention in comparison to
adjacent, nondiseased vein.
Statistical analysis. Measured values are reported as
percentages or means  standard deviation. Hemodialysis
access patency rates are calculated using Kaplan-Meier anal-
ysis and reported using current SVS criteria.3 Standard
errors are reported in Kaplan-Meier analyses. Cox propor-
tional hazard analyses were performed to identify factors
associated with outcomes. Analyses were performed using
JMP 5.0.1 software (SAS Institute, Cary, NC).
RESULTS
Patient population. We identified 73 patients with 75
central venous stenoses undergoing primary percutaneous
therapy during study period. Primary stenting (PTS) was
done in 26 patients (35% male) in 26 central venous steno-
ses, and 47 patients (45% male) underwent primary angio-
plasty (PTA) of 49 central venous stenoses. These two
groups did not differ with respect to comorbidities or other
demographics identified and evaluated (Table I). Angio-
plasty was attempted and failed in nine PTA patients, eight
of whom went on to secondary stenting at the failed inter-
vention. We defined these eight patients as treatment fail-
ures at the time of secondary stenting, although they did
achieve a period of patency after secondary stent placement.
Hemodialysis access. At the conclusion of follow-up,
cumulative access survival did not differ between PTA and
Table I. Patient demographics and risk factors
PTA PTS P
Demographics
Patients 47 26 —
Veins treated* 49 26 —
Male 45% 35% .49
Interventions 98 71 —
Interventions per treated vein 2.0  1.6 2.7  2.4 .20
Patient age (years) 57  18 57  15 .98
Follow-up (years) 3.3  0.4 2.7  0.5 .64
Comorbidities
Hypertension 76% 62% .21
Diabetes mellitus 55% 54% .92
CAD 20% 35% .18
CHF 18% 19% .93
History of smoking 20% 31% .32
PTA, Primary central vein angioplasty group; PTS, primary central vein
stenting group; CAD, coronary artery disease; CHF, congestive heart
failure.
*Two patients in the PTA group underwent bilateral central vein angioplasty
during the course of follow-up.PTS groups (P  .13; Fig 1). Age and type of hemodialysis
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the 19 failed access sites within the PTS group, three were
resected for graft infection, one was abandoned because of
several large pseudoaneurysms impairing functional access,
and one was ligated during open thrombectomy after a
percutaneous access declot that had precipitated radial ar-
tery embolization. The remaining 14 failed access sites had
been abandoned as a result of their inability to provide
consistent functional hemodialysis.
In the PTA group, 26 of the 49 access sites failed
during the study period. Two failures were the result of
graft resection for infection, one resulted from upper ex-
tremity amputation for a necrotizing soft tissue infection in
a patient with an autogenous fistula, and two sites were
abandoned because of the poor status of the access site
related to pseudoaneurysm formation and trauma from
the number of times accessed over the life of the site.
There were no significant differences between groups
with respect to the number of access sites that failed or were
censored, or the mode of access failure.
Periprocedural variables. Indications for initial inter-
vention were not significantly different between groups and
Fig 1. Hemodialysis access survival curves for the primary angio-
plasty (PTA) and primary stenting (PTS) groups. The PTA group
is depicted with closed circles and the PTS group with closed
diamonds. Access survival is not different by Kaplan-Meier analysis
(P  .13). Standard error is 10% at any time point.
Table II. Age and type of hemodialysis access and patency
Hemodialysis access PTA PTS P
Variables
Access age (years) 1.1  1.2 1.0  1.3 .88
Prosthetic (%) 59 62 .84
Patency rates (%)
1 month 84  6 80  8
3 months 76  7 63  10
6 months 62  8 54  10 .13
12 months 53  8 45  10
24 months 38  9 32  11
PTA, Primary central vein angioplasty group; PTS, Primary central vein
stenting group.included, in descending order of incidence, ipsilateral up-per extremity swelling with or without associated chest,
neck, and facial swelling; increased venous pressures while
on hemodialysis; and clinically diagnosed clotted access
(Table III). The indication was unspecified in roughly one
quarter of the primary interventions within both groups.
Considering the two groups collectively, the vessel
most commonly treated was the subclavian vein in 48%,
followed by the brachiocephalic vein in 48%, and the supe-
rior vena cava in 4%. An intergroup analysis demonstrated
no significant differences in vessels treated (Table III).
There was no significant difference in laterality of vessels
treated, and none of these patients had previously under-
gone any form of surgical decompression.
There were no periprocedural or 30-day all-cause mor-
talities in either group. One 90-day, all-cause mortality
occurred in the PTS group, 42 days after initial stent
implantation and during the same admission. This 72-year-
old patient had a history of cerebrovascular accident 12
months before the intervention and 28% cardiac ejection
fraction. On completion of a 10-mm  68-mm Wallstent
placement within the left brachiocephalic vein, the patient
was seen to have a small proximal filling defect, for which
heparin therapy was initiated. Several days later, an episode
of hypotension occurred that degenerated into ventricular
fibrillation. After stabilization of the dysrhythmia and hy-
potension, the patient was diagnosed on computed tomog-
raphy scanning with retroperitoneal bleeding. The patient
never recovered neurologic function after the event and
died 42 days after primary stent placement. Mortality was
not significantly different between groups (P  .13).
The morbidity rates for the PTA and PTS groups were
0% and 4%, respectively (P  .17). The PTS morbidity
represents one major adverse event stemming from a distal
radial artery embolization that occurred after a hemodialy-
sis access declot immediately after primary stenting. This
patient was taken urgently to the operating room for open
thrombectomy, after which flowwas re-established, and the
patient fully recovered without further negative sequelae.
Outcomes. The initial treatment of central venous
stenosis was technically successful in 82% of the PTA group
and 96% of the PTS group (P  .08). However, residual
stenosis was significantly more common with angioplasty
Table III. Periprocedural variables
PTA (%) PTS (%) P
Indication for intervention
Swelling 41 50 .45
High venous pressure 31 19 .29
Clotted access 6 12 .41
Not specified 22 19 .75
Vessel treated
Subclavian vein 43 58 .12
Brachiocephalic vein 51 42 .30
Superior vena cava 6 0 .20
PTA, Primary central vein angioplasty group; PTS, primary central vein
stenting group.(53%) than with stenting (7%; P  .001; Table IV). One
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in the PTS group, and the remaining eight required two
stents for coverage. Proper positioning was achieved in all
stent deployments. Neither immediate nor delayed migra-
tion of the stent was identified.
In the PTA group, 28 of the initial 49 veins angioplas-
tied required at least one secondary intervention after the
loss of primary patency, including six that underwent im-
mediate secondary stenting after failed initial angioplasty.
Of the remaining 21 veins angioplastied, 14 remained
primarily patent at the end of follow-up, and seven failed
primarily between 0 and 18 months after the initial angio-
plasty.
Among the PTS patients, 13 of the initial 26 veins
stented required at least one secondary intervention after
loss of primary patency. Of the remaining 13 veins stented,
five remained primarily patent at the end of follow-up, but
eight failed primarily between 0 and 5 months after initial
stenting. Reinterventions in the PTS group involved 17
additional stent deployments in 10 of the 13 patients
undergoing repeat intervention.
Of the 18 patients in the PTA group who had failed at
the conclusion of follow-up, eight underwent stenting of
the central venous lesion because of lesion recalcitrance. In
addition to the six secondarily stented at the initial inter-
vention, two were secondarily stented later, both occurring
at the third percutaneous intervention. As defined in the
Methods section, these stenting events were considered
failures for the purpose of PTA group follow-up, which was
ended at the stenting event. Otherwise, reinterventions in
the PTA group did not involve placement of any stent.
Of the six patients who failed initial angioplasty and
were therefore treated with secondary stenting, four failed
between 42 and 421 days. One of these four was left
occluded, and the remaining three underwent reinterven-
tion, including repeat stent placement in two and a failed
attempt at angioplasty in one. This yielded primary and
Table IV. Angioplasty and stenting outcomes
PTA (%) PTS (%) P
Procedural success
Technical success 82 96 .08
Residual stenosis 53 7 .001
Primary patency rates
1 month 76  6 76  9
3 months 58  7 46  10
6 months 45  8 38  10 .48
12 months 29  8 21  8
24 months 7  5 7  6
Assisted primary patency rates
1 month 81  6 84  7
3 months 77  6 72  9
6 months 77  6 55  10 .08
12 months 73  7 46  10
24 months 57  9 29  10
PTA, Primary central vein angioplasty group; PTS, primary central vein
stenting group.assisted primary patency rates of 40%  22% at both 6months and 1 year by Kaplan-Meier analysis for these six
patients.
Primary and assisted primary patency rates for the PTA
and PTS groups are listed in Table IV. Neither primary
patency (Fig 2) nor assisted primary patency (Fig 3) was
significantly different between groups, although the as-
sisted primary patency for the PTS group trended toward a
lower rate when compared with the PTA group (P  .08;
Fig 3).
Cox proportional hazards analysis was used to investi-
gate the impact of preoperative and perioperative factors
related to outcomes of primary, assisted primary, and
dialysis-access patencies. When analyzing across both the
PTS and PTA groups, we found that a history of congestive
heart failure was positively associated with lower primary
patency (risk ratio, 2.72; P  .0037) and lower assisted
Fig 2. Primary patency of central vein after angioplasty or stent-
ing. The primary angioplasty group (PTA) is depicted with closed
circles and the primary stenting group (PTS) with closed diamonds.
Primary patency is not different by Kaplan-Meier analysis (P 
.48). Hatched line indicates standard error 10%.
Fig 3. Assisted primary patency of central vein after angioplasty
or stenting. The primary angioplasty group (PTA) is depicted with
closed circles and the primary stenting group (PTS) with closed
diamonds. Assisted primary patency does not achieve conventional
statistical significant difference by Kaplan-Meier analysis (P .08).
Hatched line indicates standard error 10%.primary patency (risk ratio, 2.34; P .0357). Likewise, the
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which happened to be more common in the PTA group,
was significantly associated with lower primary patency
rates within that group (risk ratio, 2.78; P .0111) but was
not associated with assisted primary patency rates. No
preoperative or perioperative factor identified was signifi-
cantly associated with the cumulative patency rate of the
hemodialysis access site.
DISCUSSION
The clinical problem of hemodialysis access manage-
ment is large and growing. The patient population in 2003
numbered 298,101, and grew at an average annual rate of
2.6% from 1999 to 2003. Contributing to this growth is
the 8% drop in mortality rates for these patients since
1986.4 Attendant with this growing body of hemodialysis
patients is an ever-increasing clinical volume related to
hemodialysis access-related complications, including the
development of central vein stenosis. Incidences of central
vein stenosis of 11% to 40% have been reported for hemo-
dialysis patients.5-9
The cause of central venous stenosis in the dialysis
patient has been attributed to two major factors: (1) tem-
porary central venous catheterization for hemodialysis, par-
ticularly when the subclavian vein is accessed,10-13 and
(2) the high-flow state induced by the creation of an
arteriovenous shunt with resultant regions of increased
turbulence.7,14 In an effort to reduce the impact of hemo-
dialysis catheter placement, the Dialysis Outcome and
Quality initiatives (DOQI) guidelines, released in 1997 and
updated in 2000, advocated avoiding subclavian vein cath-
eterization as temporary access in all patients with chronic
renal failure.15 Since that time, our institution has adopted
the guideline as a hospital-wide policy.
The onset of central vein stenosis can substantially
complicate maintenance of hemodialysis access by increas-
ing arteriovenous access pressure1 and generating signifi-
cant local morbidity by creating extremity, chest, neck, and
even facial swelling. Aside from ligation of the fistula and
abandonment of the extremity for access, the only manage-
ment strategy before the rapid advancements in percutane-
ous therapy was open surgical treatment. Although open
methods have proven fairly durable, with 1-year primary
patencies of 80% to 86%,16,17 they bear significant morbidity
owing to lesion location within the chest. Therefore, begin-
ning in the mid 1980s, evaluation of percutaneous methods
began for the treatment of central venous stenosis.18
In this article, we have retrospectively reported our
experience in percutaneously treating central venous steno-
ses in patients with ipsilateral hemodialysis access sites
during a 9-year period. It happens that during this time,
interest was increasing both locally and internationally in
primary stenting of central venous lesions in an effort to
reduce the recurrence rates seen in these lesions when
treated with angioplasty alone.
This evolution in management culminated with the
publication by Haage et al6 of their experience in treating
50 dialysis-dependent patients with primary Wallstentplacement. Their report in 1999 of primary Wallstent
placement in patients with symptomatic arteriovenous
shunt dysfunction owing to central venous obstruction
represented the best patency reported to that date, with
primary stent patency at 1 year of 56% and cumulative stent
patency at 1 year of 97%.6 Unfortunately, no one since has
reported results as successful as those of the Haage group.
These factors coincided with an increase, and then
decrease, in the proportion of patients treated with primary
stenting in our institution during the study period, creating a
unique opportunity to compare outcomes of these twometh-
ods. Althoughour study groupswere nonrandomized and the
treatment method appeared to be operator-dependent, we
were unable to identify any significant differences in lesion
characteristics or group demographics that might account
for any differences in outcome. We therefore postulate that
our results represent the real-world experience of both
primary stenting and primary angioplasty in the population
of hemodialysis-dependent patients with central venous
stenosis. Our results can be summarized into four basic
points:
1. Both treatment methods were safely performed with
high rates of initial success.
2. With respect to primary patencies, primary stenting and
primary angioplasty were equivalent, although a signif-
icantly higher rate of residual stenosis was tolerated in
the PTA group.
3. Assisted primary patency rates were equivalent, al-
though a trend toward higher assisted patency rates for
the PTA group was noted (P  .08).
4. With respect to overall ipsilateral hemodialysis-access
survival, primary stenting and primary angioplasty were
equivalent.
Regarding the endovascular treatment of central vein
stenosis, our results were consistent with essentially all
reports on this subject, demonstrating safety and initial
efficacy, and in contrast to the morbidity of open surgical
reconstruction, reported as high as 30%.19-20
Previous studies reporting outcomes of endovascular
treatment for central vein stenosis fall into three broad
categories: those reporting angioplasty with or without
stenting after failed angioplasty or because of recurrent
stenosis, those reporting only stenting but after failed angio-
plasty, and those reporting stenting as the initial therapy.
The aforementioned study by Haage et al,6 along with
those of Shoenfeld et al,21 Quinn et al,22 Mickley et al,23
and Oderich et al,24 represent the studies to date reporting
outcomes of primary stenting. The 1-year outcomes re-
ported by these groups include primary patencies of 11%
to 70% and assisted or secondary patencies of 71% to
100%.6,22-25
Although our own 1-year primary patency of 21% falls
into the lower range of primary patencies previously re-
ported, our 1-year assisted patency rate of 46% is notably
lower than those previously reported. It is unclear why this
discrepancy exists. In their study of primary stent placement
in 14 patients, Mickley et al23 reported patencies on the
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differed from the others in that they routinely administered
heparin anticoagulation to an activated partial thrombo-
plastin time of 60 to 90 seconds for 3 days after stent
placement. It seems unlikely, however, that this difference,
in this number of patients, would account for a higher
patency 12 months out from the primary stent placement.
The only universal difference between our study and the
others is that whereas ours had an average follow-up of 2.7
years for those patients primarily stented, the reported
average follow-up for the other primary stenting studies
was 9 to 18 months. This shorter-term follow-up may in
part account for the difference between our assisted patency
rates and the others when evaluated 12 months beyond
primary stenting.
Although not directly comparable with our report or
others evaluating primary stenting, several groups have
reported their studies on patients undergoing stenting after
suboptimal angioplasty or early recurrence after angio-
plasty. They reported 1-year primary patencies of 14% to
25%, with assisted or secondary patency rates at 1 year of
33% to 67%,26-30 which is consistent with our 1-year pri-
mary and assisted primary patency rates for the PTS group.
It is also consistent with the 40% primary and assisted
primary patencies at 1 year for our six patients undergoing
secondary stenting after failed initial angioplasty, although
with the small number of patients at risk at 1 year, the
standard error is admittedly high (22%).
Patencies reported for secondary stenting are much
shorter than those reported for primary stenting, most
likely because they represent a subset of lesions that are
more recalcitrant to endovascular treatment, thereby skew-
ing the patency rates downward. This serves to underscore
the effect that patient, or rather, lesion selection has on the
reported patency rates of these endovascular techniques
when reported with the small number of patients repre-
sented in most of these studies.
The report of secondary stenting noted by Aytekin
et al28 differs from other studies of central venous stenting,
including our own, in that 10 of their 14 patients evaluated
were stented with the Memotherm nitinol stent (Bard
Angiomed), whereas other reports of stenting in the central
veins used stainless steel stents almost exclusively. In these
14 patients, 1-year primary patency was 14% and secondary
patency was 56%,28 results consistent with other reports of
secondary stenting in this setting. Given these results in this
single, small series of patients, no conclusions can yet be
drawn on the impact of nitinol stenting in this patient
population.
Much of the literature reporting percutaneous angio-
plasty as the primary management of central vein stenosis
also includes patients in whom stent deployment was per-
formed in cases of suboptimal angioplasty, usually defined
as residual stenosis of 30% to 50%. This makes comparison
of the results of such studies with a primary stented group,
such as our PTS group, challenging because the impact of
the stent when placed at the initial intervention, whether
beneficial or not, could be expected to skew the results intothe direction of the primarily stented group. For this rea-
son, we elected to end follow-up of our PTA group at the
time of subsequent stent placement, if it occurred, and
consider that as a treatment failure. We recognize that this
creates an inherent bias in favor of the PTS group because
of the potential abandonment of vessels salvageable by
secondary stenting. Based on that definition, we achieved
1-year primary and assisted primary patency rates of 29%
and 73%, respectively in our PTA group.
These patency rates are in the range of those previously
reported. Glanz et al30 reported a 30% primary patency rate
at 1-year follow-up in 13 subclavian vein lesions among 19
patients with 29 axillary and subclavian vein dilations.
Lumsden et al9 similarly reported a 17% 1-year primary
patency rate after percutaneous treatment of 25 central
venous stenoses. Quinn et al,23 in their prospective ran-
domized trial of PTA vs PTA with stenting, reported a
1-year primary patency of 12% and a 1-year secondary
patency of 100% in patients undergoing primary angio-
plasty alone. As in the Quinn et al study, we showed no
improvement in patency rates with stenting. This furthers
the conclusion that primary stenting does not benefit long-
term outcomes in these patients. Given the lackluster pa-
tencies in our six patients who underwent secondary stent-
ing after failed angioplasty, it seems that the need to stent
also carries a poor prognosis.
Our study does not address the reasons why stenting
might negatively impact assisted primary patency; however,
others have reviewed the reported differences in the biol-
ogy of in-stent restenosis compared with that after balloon
angioplasty.31 These differences include generalized injury
to the vessel at the site of the stent, with more focal injury at
the site of struts, followed by fibrinogen coating and the
adherence of platelets and leukocytes. The vessel subse-
quently has a more prolonged and robust intimal hyper-
plastic response, with a prolonged adventitial response
marked by giant cell body formation. Whether these differ-
ences have a role in divergent outcomes between central
venous angioplasty and stenting has yet to be defined.
Finally, although we agree with Haage et al6 and Vor-
werk et al25 that a hemodialysis-access site may fail for many
other reasons while the treated central vein remains fully
patent,32 we recognize that the primary reason for these
patients to undergo treatment of these lesions is to manage
symptoms of venous hypertension while preserving the
arteriovenous access. In that sense, functional hemodialysis
access patency is the bottom-line. We therefore chose to
evaluate cumulative ipsilateral access utility, where we
found a 1-year patency rate of 53% for the PTA group and
45% for the PTS group, a small difference that was not
significant.
Based on these results, we conclude that primary stent-
ing does not add to themanagement of central vein stenosis
in the hemodialysis patient. Although our primary stenting
assisted patency rates fell below those previously reported,
our PTA group demonstrated assisted patency rates fully in
the range of previous reports for primary stenting, thus
calling into question any assertion about the superiority of
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was not superior to angioplasty in any of the outcomes
evaluated.
Given the additional cost of stenting, one could reason-
ably advocate primary stenting only if it were an improve-
ment compared with angioplasty in some meaningful
outcome. The evolution of newer stent technologies,
including nitinol stents, may improve the outcomes of
central venous stenting, perhaps by altering the vessel’s
reaction to stent placement; however, no large body of data
currently exists for these stents in the central venous circu-
lation. Taylor et al33 have reported a comparison of stent
designs, including steel vs nitinol, in a porcine artery model
and found that nitinol stents doubled neointimal area and
thickness as a result of extracellular matrix expansion but
that lumen area was not different owing to expansion of the
stent and, consequently, the artery. Conversely, Carter
et al34 reported a reduction of neointimal area and percent-
age stenosis in porcine coronary arteries when comparing
nitinol stents with steel stents. The true impact of newer
stent materials and designs in humans remains undefined.
It should be noted that we evaluated primary stenting
and primary angioplasty and defined stenting after failed
angioplasty as a treatment failure. There are certainly in-
stances when immediate elastic recoil or no appreciable
effect after angioplasty necessitates secondary placement of
a central venous stent to establish flow and reduce venous
hypertension.
In addition, this study period did not include our more
recent usage of cutting balloon angioplasty within central
veins that, like newer stent technology, may improve upon
current endovascular outcomes.
Finally, it should be noted that the major limitation of
this study is that it is nonrandomized. The choice of pri-
mary stent placement was operator-dependent, because
members of our group each began adopting the technology
when others in the 1990s were reporting initial success. No
faculty member present during our study period was dis-
proportionately involved in either the PTA or PTS study
group, nor did we identify any significant differences in
lesion characteristics or group demographics that might
account for any differences in outcome. Nevertheless, it is
possible that primary stent placement was chosen for some
unquantified variable that might affect stent patency, thus
depressing primary stenting patency rates and hemodialysis
access survival rates. Caution must therefore be advised in
applying these results to the greater patient population.
CONCLUSION
Endovascular treatment with angioplasty or stenting
for central venous stenosis is safe, with low rates of technical
failure. Multiple additional interventions are the rule with
both treatment modalities. Although neither offers truly
durable outcomes, stenting does not have higher patency
rates than angioplasty and does not add to the longevity of
ipsilateral hemodialysis access sites. Given its greater cost
and known potential consequences of bridging patent in-
ternal jugular veins or extending medially into the superiorvena cava from the brachiocephalic vein, in the absence
demonstrable benefit primary, stenting of central venous
stenoses should not be considered to add to the manage-
ment of hemodialysis patients.
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